Amylyx Pharmaceuticals (AMLX) to Announce Quarterly Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) will issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative return on equity of 15.51% and a negative net margin of 17.86%. The firm had revenue of ($1.02) million during the quarter, compared to analysts’ expectations of $18.83 million. During the same quarter last year, the business earned $0.31 earnings per share. On average, analysts expect Amylyx Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Amylyx Pharmaceuticals Trading Up 1.9 %

AMLX stock traded up $0.11 during trading on Tuesday, reaching $5.81. The stock had a trading volume of 787,893 shares, compared to its average volume of 2,026,456. The stock’s 50 day moving average is $3.43 and its two-hundred day moving average is $2.44. The firm has a market cap of $395.54 million, a PE ratio of -2.33 and a beta of -0.70. Amylyx Pharmaceuticals has a 52 week low of $1.58 and a 52 week high of $19.95.

Insider Buying and Selling

In other news, CEO Justin B. Klee sold 18,589 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $3.20, for a total transaction of $59,484.80. Following the sale, the chief executive officer now owns 3,120,569 shares in the company, valued at $9,985,820.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Camille L. Bedrosian sold 11,442 shares of the stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $3.20, for a total transaction of $36,614.40. Following the completion of the transaction, the insider now directly owns 143,801 shares of the company’s stock, valued at approximately $460,163.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Justin B. Klee sold 18,589 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $3.20, for a total value of $59,484.80. Following the transaction, the chief executive officer now owns 3,120,569 shares of the company’s stock, valued at $9,985,820.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 11.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on AMLX shares. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Amylyx Pharmaceuticals in a research report on Friday, October 18th. Leerink Partners set a $4.00 price objective on Amylyx Pharmaceuticals and gave the stock a “market perform” rating in a research note on Friday, October 18th. The Goldman Sachs Group lifted their target price on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a research report on Friday, July 12th. Finally, Bank of America raised Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the company from $4.20 to $10.00 in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $14.57.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.